Trasplante hepático por hepatitis autoinmune en Paraguay

Nelson Arellano; Marcos Girala; Sebastián Diaz; Carine Arellano

doi:10.18004/

Authors

Nelson Arellano Unidad de Trasplante Hepático, Hospital de Clínicas. Facultad de Ciencias Médicas, Universidad Nacional de Asunción. San Lorenzo, Paraguay
Marcos Girala Departamento de Gastroenterología y Hepatología, Hospital de Clínicas. Facultad de Ciencias Médicas, Universidad Nacional de Asunción. San Lorenzo, Paraguay.
Sebastián Diaz Servicio de Urgencias. Hospital de Clínicas. Facultad de Ciencias Médicas. Universidad Nacional de Asunción. San Lorenzo, Paraguay
Carine Arellano Unidad de Trasplante Hepático, Hospital de Clínicas. Facultad de Ciencias Médicas, Universidad Nacional de Asunción. San Lorenzo, Paraguay

DOI:

https://doi.org/10.18004/

Keywords:

Autoimmune Hepatitis, liver transplant, autoantibodies, Paraguay

Abstract

Introduction: Liver transplantation is an effective treatment for patients with chronic or acute terminal liver disease, including autoimmune hepatitis (HAI). Autoimmune hepatitis is a heterogeneous group of liver diseases that most frequently affect the female sex, characterized by necrotic-inflammatory lesions, immunologically mediated and with multifactorial origin. Objectives To determine the prevalence, the demographic characteristics, the severity of liver disease and the diagnosis of HAI treated with liver transplants in Paraguay. Material and methods: Observational, descriptive, cross-sectional study with prospectively collected data of adult patients of both sexes, treated with liver transplant for autoimmune hepatitis in decompensated cirrhotic stage, in the Liver Transplant Unit of the Hospital de Clínicas, Faculty of Medical Sciences, National University of Asunción, from March 2015, until October 2018. Results: a total of 12 patients underwent liver transplantation. The majority of transplant patients were female, corresponding to 58.3% (7/12). The average age of the recipients was 39.4 years (19-61). The indications for liver transplantation were: autoimmune hepatitis in decompensated cirrhotic stage in 50% (6/12) of cases, primary sclerosing cholangitis in 16.6% (2/12), cryptogenic cirrhosis in 16.6% (2 / 12), post colecistectomy surgical injury of the bile duct with secondary biliary cirrhosis in one case and finally, one case of fulminant hepatitis secondary to pharmacological hepatotoxicity. The patients transplanted for Autoimmune Hepatitis had an average age of 29.8 years (19-51) and the predominant sex was female, corresponding to 83.3% (5/6)of cases.

References

1. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999;281:1900–1905.

2. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54–66.

3. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011;55:171–182.

4. Waldenström J. Leber, Blutproteine und Nahrungseiweiss. Dutch Gesellsch Verdau Stoffwechselkr. 1950;15: 113– 121.

5. Mackay I.R, Taft L.I, Cowling D.C. Lupoid hepatitis. Lancet. 1956;2: 1323– 1326.

6. Whittingham S.F, Irwin J, Mackay I.R. Smooth muscle autoantibody in “auto-immune” hepatitis. Gastroenterology. 1966;51: 499– 505.

7. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol 2003;18:1118–1128.

8. Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232–1240.

9. Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010;25:1681–1686.

10. Delgado J-S, Vodonos A, Malnick S, Kriger O, Wilkof-Segev R, Delgado B, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis 2013;14:611–618.

11. van Gerven NMF, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al. Epidemiology and characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014;49:1245–1254.

12. Soloway R.D, Summerskill W.H.J, Baggenstoss A.H, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63: 820– 833.

13. Mistilis S.P, Skyring A.P, Blackburn C.R.B. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med. 1968;17: 214– 223. 32.

14. Murray-Lyon I.M, Stern R.B, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1: 735– 737.

15. Manns MP et al. Diagnosis and Management of Autoimmune Hepatitis. Hepatology 2010;51:2193-2213.

16. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005; 5:307-313.

17. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 ; 31 : 929-938.

18. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–176.

19. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006; 43:S132-144.

20. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97:2402–2407.

21. Minuk GY, Liu S, Kaita K, Wong S, Renner E, Rempel J,

et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 2008;22:829–834.

22. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 2012;46:155–161.

23. Levy C, Naik J, Giordano C, Mandalia A, O’Brien C, Bhamidimarri KR, et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol 2014;12: 1398–1405.

24. Ichai P, Duclos-Valle J, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13: 996– 1003.

25. Strassburg C. Autoimmune Hepatitis. En: Boyer T, Manns M, Sanyal A. Zakim and Boyer’s Hepatology A textbook of Liver Disease. 6a Edición. Elsevier-Saunders, 2012: 712-737.

26. Sassi K. Transplantation in Autoimmune Hepatitis. En: Busuttil, Ronald W.; Klintmalm, Goran B. Transplantation of the Liver 3ra. Edición. Elsevier Health Sciences, 2015:186.

27. Erwin Buckel y col. “Dieciséis años de Experiencia de Trasplante Hepático en Clínica Las Condes”. Rev. Med. Clin. Condes, 2010; 21(2) 267-272.

28. Haddad L, Marciano S, Cleres M, Zerega A, Piñero F, Orozco F, Braslavsky G, Mendizabal M, Gondolesi G, Gil O, Silva M, Mastai R, Imventarza O, Descalzi V, Gadano A. Characteristics of Liver Transplantation in Argentina: A Multicenter Study. Transplant Proc. 2018 Mar;50(2):478-484.

29. Andraus W, Canedo BF, D’Alburquerque LA Hepatobiliary Living donor liver transplantation in Brazil current state. Surg Nutr. 2016 Apr;5(2):176-82.

30. Santos O et al. “Experiencia de Trasplante Hepático en Latinoamérica: en un Centro de Colombia”. Colombia Médica. Vol. 46 N°1, 2015.

31. José Carlos Chaman y col. “10 años de Trasplante Hepático en el Perú”. Rev. Gastroenterol. Perú, 2010; 30-4: 350-356.